The 2026 events calendar for nicotine and reduced-risk products ran from FDA's small manufacturer roundtable in February to an online seminar with CTP's Office of Science Director in November. Over the year, the tone shifted from frustration over delays toward clearer expectations, more open dialogue and cautious optimism.
The scientific requirements have not been lowered, but regulators are now more open about how they apply them and about the problems holding the category back. Below we look back at what we heard at each event and the themes common to all of them.
The year opened on February 10 with CTP's full-day roundtable for small ENDS manufacturers. FDA's message was that the bar is not being lowered, but that it is becoming more transparent about how the bar is applied.
Product characterization was positioned as the foundation of every application: design specifications with defined limits, complete ingredient lists, validated HPHC methods and stability data across the claimed shelf life. There are still no numerical APPH thresholds or ENDS product standards, and substantial equivalence remains effectively unavailable for ENDS because valid predicate products do not exist. Quality systems must be demonstrably operational, not just SOPs on paper, and pharmacology and adult-benefit evidence must be designed in from the start.
Toxicology carries equal weight. FDA endorsed Excess Lifetime Cancer Risk (ELCR) assessment, confirmed there will be no static "safe" ingredient list, and cautioned that a negative Ames result on an aerosol mixture may be of limited value and does not indicate low lifetime carcinogenicity risk. Where data are limited, conservative approaches such as the 1.5 µg/day Threshold of Toxicological Concern are typically applied. Commissioner Makary also made an unscheduled appearance, stressing that youth protection remains the priority but that predictability for industry matters too.
WNC asked how evidence can be turned into real progress on harm reduction, and speakers repeatedly came back to the need for regulators, scientists and industry to align. With real-world data from Sweden and Japan, the debate has moved from whether harm reduction works to whether regulation is keeping pace with the science.
Investment is increasingly shaped by regulatory credibility, and slow, fragmented approvals delay the introduction of compliant products, enabling the growth of illicit markets, which can potentially respond more quickly to consumer demand. Speakers noted a gap between the science and public perception: the evidence is increasingly robust, but unclear claims, headline-driven narratives and non-compliant products continue to erode trust. Real-world evidence was seen as valuable but demanding, needing purposeful design and sitting alongside established science rather than replacing it. Post-market surveillance borrowed from pharma and medical devices was suggested as a model, though reporting remains inconsistent and underused.
The closing session called on industry to engage policymakers more effectively, put credible voices such as healthcare professionals at the front, and collaborate at category level.
ATNF was notable for the constructive tone of its discussions. The innovation panel argued that clear regulatory frameworks guide innovation rather than hinder it, stressing early-stage testing and the fundamentals of scale-up: a skilled team, sufficient investment and a strong focus on the consumer. A session on AI argued that companies need to adopt it or risk falling behind, with the caveat that outputs need continuous validation.
Day two was effectively "FDA Day". Dr. Bret Koplow and Cristi Stark outlined plans for "lessons learned" guidance from the nicotine pouch pilot, applicable across product categories, and a more streamlined review with more two-way communication. The most significant point was that the PMTA acceptance queue is effectively obsolete, which ends the use of placeholder submissions. Phased submissions now need a substantial weight of APPH evidence to avoid rejection.
The 10th annual E-Vapor, Nicotine and Tobacco Law Symposium focused on how the regulatory frameworks work in practice. Flavored ENDS face a markedly higher evidentiary threshold because of youth initiation concerns, and many applications still fail on fundamentals: gaps in product characterization, weak stability data and thin manufacturing detail. Design, naming, packaging and marketing were all assessed in terms of youth prevention.
Day two focused on manufacturing: control and consistency, robust quality agreements between brand owners and contract manufacturers, and the "five Ps" of GMP. A product that cannot be shown to match its authorized specification risks being treated as a different product.
Nicotine analogs were debated, with growing scientific and media scrutiny on one side and emerging industry data and age-gating strategies on the other. Most expect FDA to address them formally. A Canadian comparison closed the event. There, pouches are regulated under the Food and Drugs Act rather than as tobacco products, with two routes: pouches containing 4 mg or less are licensed as non-prescription natural health products for smoking cessation, while anything above 4 mg would be regulated as a prescription drug. Authorized pouches are limited to mint or menthol flavors and sold from behind the pharmacy counter.
Miami opened with an operational update from CTP. Cristi Stark's central point was that applications usually fail not because standards are impossibly high, but because they lack the information needed for review. Acceptance review now targets around 21 days, with AI used to triage information and every output checked by a human. Substantive review still runs beyond 180 days, but FDA is more willing to resolve issues during review rather than through deficiency letters.
Benjamin Apelberg set out three scientific pillars: product characterization, manufacturing consistency and abuse liability. Bridging across SKUs is acceptable where the tested product is shown to be representative, and marketing must clearly target adults. Panels urged early engagement through pre-submission meetings.
Enforcement dominated later sessions. FDA's new enforcement priorities guidance sets out three categories: authorized, lower-priority unauthorized and higher-priority unauthorized products. The general view was that thin, placeholder PMTAs will no longer succeed, and that enforcement is needed to make compliance worth pursuing.
GTNF reflected continued frustration but also some signs of change. Supply-chain panels argued that regulation, not logistics, is now the biggest risk. BAT's Kingsley Wheaton reminded delegates that "safer" is comparative, and that conflating nicotine with combustion obscures the real source of harm.
The illicit market was a recurring thread. Lillian Ortega estimated that unauthorized products make up around 70% of US ENDS retail sales, with only a small number of authorized ENDS products available, largely tobacco and menthol flavored. Australia was presented as a warning: prohibition-led policy has fueled an illicit trade tied to organized crime and around $10bn in annual excise losses. New Zealand, by contrast, showed how constructive engagement helped bring daily smoking down to 6.8%. The European TPD panel warned that science is being sidelined despite strong support for harm reduction among the 82,000 consultation responses, with a TPD3 draft expected by the end of 2026.
Bret Koplow, now permanent CTP Director, closed with three priorities: preventing youth initiation, helping adults quit or switch, and communicating the continuum of risk. Over 99% of applications have lacked basic evidence, he said, but the backlog is down 70% and import refusals have risen from about 100 in FY2023 to over 9,000 in FY2025.
At FDLI, Dr. Koplow spoke candidly about the Office of Science losing scientists to better-paid FDA centers, and flagged youth-facing marketing, from rewards programs to motorsport sponsorships, as a priority. Office of Science leaders explained the supplemental PMTA pilot: single-cycle review, generally without deficiency letters, with changes grouped as minor, moderate or complex. Changes to the nicotine itself remain largely out of scope, but identical-supplier changes may count as minor, and alternate suppliers identified during review could be authorized together. Bridging needs a real scientific rationale, not just a cross-reference; for pouches, pH, free nicotine and delivery are key. CTP is also exploring voluntary consensus standards, including CORESTA.
Beyond the conferences, FDA announced on September 28 that it will evaluate changes to the PMTA framework, potentially replacing the 2021 rule. Recent authorizations, including JUUL2 in late August and further nicotine pouches, showed faster reviews in practice. Yet a GAO report called for better tracking of review timeliness, public health groups challenged the enforcement priorities guidance, and litigation by Altria subsidiaries Helix and NJOY was paused on October 8 while FDA reconsiders its rules.
In November, Dr. Matthew Farrelly, Director of CTP's Office of Science, presented to the research community at TOPS and took questions. Although the session was aimed at academics, it gave a useful view of how FDA reviewers assess applications, and it came shortly after FDA announced it would reconsider the PMTA framework.
Farrelly repeatedly stressed product-specific evidence. For any new product, FDA builds a full toxicological risk profile covering cancer and non-cancer risks and HPHC levels and calculates cancer risk from the ingredients in that specific product rather than relying on category generalizations. He noted that some products reviewed had estimated lifetime cancer risks similar to or greater than cigarettes. Applicants are expected to supply HPHC data and abuse liability studies themselves. Where exposure data are missing, FDA applies its own standard use assumptions, and for ingredients with no inhalation data it relies on animal studies or computational methods.
Stability was also raised. FDA needs to understand how nicotine, humectants, preservatives and the container closure system affect microbial and chemical stability, TSNA formation and shelf life, and Farrelly said this is not unique to the substantial equivalence pathway. He singled out microbial risk for pouches, snus and e-liquids, naming bacterial endotoxins and fungal glucans.
For pouches, FDA has found that nicotine delivery and abuse liability depend on flavors and other materials, not just nicotine content and pH. Bridging between products is possible, but only with careful assessment and supporting data. For ENDS with adjustable power settings, FDA needs HPHC and abuse liability data across those settings.
Asked what PMTA reviews had taught FDA, Farrelly said over 99% of applications have lacked entire categories of evidence, the same point Dr. Koplow made at GTNF. Our reading is that whatever replaces the 2021 rule, the scientific evidence FDA expects will not change much.
Looking across the year, seven themes stood out:
FDA's messaging is more encouraging than it has been for some years. What matters in 2027 is whether this turns into predictable guidance and PMTA decisions. At Broughton, we support manufacturers with accredited analytical testing, stability studies, toxicological risk assessments and regulatory expertise. Get in touch to discuss your plans for 2027.